The Effect of Linomide, an Immunoregulator in Experimental Autoimmune Diseases, on Humoral Antibody Responses in Mice

References

• Kalland T., Aim G., Stalhandske T. Augmentation of mouse natural killer cell activity by LS2616, a new immunomodulator. J. Immunol 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors: Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol 1990; 144: 4472–4476
   PubMed Web of Science ®Google Scholar
• Stalhandske T., Kalland T. Effects of the novel immunomodulator Linomide (LS2616) on the delayed hypersensitivity reaction to bordetella pertussis in the rat. Immunopharmacology 1986; 11: 87–92
   PubMed Web of Science ®Google Scholar
• Larsson E. L. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int. J. Immunopharmacol 1989; 9: 425–431
   Web of Science ®Google Scholar
• Bengtsson M., Simonsson B., Carlsson K., Nilsson B., Smedmyr B., Termander B., et al. Stimulation of NK cell, T cell and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992; 53: 882–888
   PubMed Web of Science ®Google Scholar
• Harning R., Koo G. C., Szalay J. Immune regulation of metastases from in vivo derived syngeneic murine melanoma. Reg Immunol 1990; 3: 97–102
   PubMedGoogle Scholar
• Wanders E., Larsson E. L., Gerdin B., Tufveson G. Abolition of the effect of cyclosporine on rat cardiac allograft rejection by the new immunomodulator LS2616 (Linomide). Transplantation 1989; 47: 216–217
   PubMed Web of Science ®Google Scholar
• Tarkowski A., Gunnarson K., Stalhandske T. Effect of LS2616 administration upon autoimmune disease of (NZBXNZW) F1 hybrid mice. Immunology 1986; 59: 589–594
   PubMed Web of Science ®Google Scholar
• Bjork J., Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in type II collagen arthritis model in mice. Agents-Actions 1989; 27: 319–321
   PubMedGoogle Scholar
• Kleinau S., Larsson P., Bjork J., Holmdahl R., Klareskog L. Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clin Exp Immunol 1989; 78: 138–142
   PubMed Web of Science ®Google Scholar
• Karussis D. M., Lehmann D., Slavin S., Vourka-Karus-Sis U., Mizrachi-Koll R., Ovadia H., et al. Successful treatment of chronic relapsing experimental autoimmune encephalomyelitis by the synthetic immunodulator quinoline-3-carboxamide (Linomide). Proc Natl Acad Sci 1993; 90: 6400–6404
   PubMed Web of Science ®Google Scholar
• Karussis D. M., Lehmann D., Slavin S., Vourka-Karus-Sis U., Mizrachi-Koll R., Ovadia H., et al. Inhibition of acute, experimental autoimmune encephalomyelitis with Linomide (LS-2616), a synthetic immunodulator. Ann Neurol 1993a; 34: 654–660
   PubMed Web of Science ®Google Scholar
• Gross D. J., Sidi H., Kalland T., Rosemann E., Weiss L., Slavin S. Prevention of diabetes in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994; 37: 1195–1201
   PubMed Web of Science ®Google Scholar
• Slavin S., Sidi H., Weiss L., Rosenmann E., Kalland T., Gross D. Linomide-a new treatment for autoimmune diseases-the potential for treatment of type I diabetes. Diabetes Metabolism Reviews 1993; 9: 311–315
   PubMedGoogle Scholar
• Bergh J., Totterman T. H., Termander B., Jansson T., Nilsson B. (1989) Marked activation of the immune system by Linomide in cancer patients. A phase I study. Presented as a poster at the 5th ECCO-Meeting, London, September, 1989, 3–7
   Google Scholar
• Inman J. K. Thymus-independent antigens: the preparation of covalent, hapten-ficoll conjugates. J. Immunol. 1975; 114: 704–709
   PubMed Web of Science ®Google Scholar
• Lees A., Finkelman F., Inman J. K., Witherspoon K., Johnson P., Kennedy J., et al. Enhanced immuno-genicity of protein dextran conjugates. I. Rapid stimulation of enhanced antibody response to poorly immunogenic molecules. Vaccine 1994; 12: 1160–1166
   PubMed Web of Science ®Google Scholar
• Merrifield R. B. Automated synthesis of peptides. Science 1965; 150: 178–185
   PubMed Web of Science ®Google Scholar
• Mozes E., Dayan M., Zisman E., Brocke S., Licht A., Pecht I. Direct binding of a myasthenia gravis related epitope to MHC class II molecules on living murine antigen-presenting cells. EMBO J 1989; 8: 4049–4052
   PubMed Web of Science ®Google Scholar
• Hudson L., Hay F. Practical Immunology, 3rd Edition. Blackwell Scientific Publications, London 1989, Chapter 6
   Google Scholar
• Lees A., Morris S. C, Thyphronitis G., Holmes J. M., Inman J. K., Finkelman F. D. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 1990; 145: 3594–3600
   PubMed Web of Science ®Google Scholar
• Fridkis-Hareli M., Teitelbaum D., Gurevich E., Pecht I., Brautbar C., Kwon O. J., et al. Direct binding of myelin basic protein and synthetic copolymer I to class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc. Natl. Acad. Sci. USA 1994; 91: 4872–4876
   PubMed Web of Science ®Google Scholar
• Wortis H. H., Teutsch M., Higer M., Zheng J., Parker D. C. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc. Natl. Acad. Sci. USA 1995; 92: 3348–3352
   PubMed Web of Science ®Google Scholar
• Spetz-Hagberg A. L., Larsson-Sciard E. L. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after Linomide treatment. Res. Immunol. 1989; 140: 517–525
   PubMedGoogle Scholar
• Spetz-Hagberg A. L., Goldschmidt T. J., Stalhandske T., Larsson-Sciard E. L. Amelioration of intrathy-mic T-cell development and peripheral T-cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator. International Immunology 1990; 2: 645–650
   PubMed Web of Science ®Google Scholar
• Lehmann D., Karussis D. M., Misrachi-Koll R., Fluo-Resco D., Ovadia H., Abramsky O. Oral administration of Linomide reduces the number of MAC-I+ macrophages and inhibits antigen presentation, (Abstract). 24th Annual Meeting of the Israel Immunological Society. 1994
   Google Scholar